Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

84.59 +0.42 (+0.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains
Cocrystal Pharma Inc (NASDAQ: COCP) has announced laboratory-based results for its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205. A third-party... 
Via Benzinga
Exposures COVID-19
95 Firms Going Ex-Dividend Next Week, Including Merck, Gilead Sciences And Public Storage
Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to be eligible to receive its next dividend. 
Via Talk Markets
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
'Halftime Report' Traders Share Their Thoughts On Gilead, IBM And More
On CNBC's "Fast Money Halftime Report," Josh Brown said ICICI Bank Ltd (NYSE: IBN) looks like it's going higher. The long-term trend in the name looks great and... 
Via Benzinga
5 Top ETFs With Exposure To Biogen
Here is a look at five ETFs with large exposure to Biogen shares. 
Via Talk Markets
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that... 
Via Benzinga
Exposures Product Safety
Gilead's Trodelvy New Subgroup Data Shows Benefit in Second-Line Breast Cancer Patients
Gilead Sciences Inc (NASDAQ: GILD) has announced new data from the Phase 3 ASCENT study evaluating Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory... 
Via Benzinga
NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure
NRx Pharmaceuticals (NASDAQ: NRXP) has applied with FDA requesting Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for critically ill COVID-19... 
Via Benzinga
Exposures COVID-19 Product Safety
Could Nano-X Be a Millionaire-Maker Stock?
Nano-X is not a safe investment -- it's a highly risky one. But its potential upside is incredible. 
Via The Motley Fool
Is It Too Late to Buy the Most Promising Pipeline in the Pharma Industry?
Fast-growing AstraZeneca might make an interesting addition to your portfolio. 
Via The Motley Fool
Can This Forgotten Coronavirus Stock Make You Rich?
Despite strong headwinds, there may be hope for this biotech. 
Via The Motley Fool
Exposures COVID-19
Market Briefing For Tuesday, May 25
Seasonal bias kicked-in, to the upside, ahead of Memorial Day, primarily it seems led by rotational rebounds in the usual suspects of momentum stocks, but also as Oil moved above 65 / bb,; suggesting... 
Via Talk Markets
NGM Stock Crashes As NASH Drug Joins Gilead, Genfit With Notable Flops
NGM Biopharmaceuticals joined a raft of biotech companies with a failed hepatitis treatment on Monday, leading NGM stock to crash. 
Via Investor's Business Daily
NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) is a clinical-stage biopharma developing liver and metabolic disorders therapies. Its stock is down just 6.2% year-to-date... 
Via Benzinga
'Fast Money' Traders Weigh In On IBB And Gilead
On CNBC's "Fast Money," Tim Seymour spoke about a possible break out in iShares Nasdaq Biotechnology ETF (NASDAQ: IBB). He said traders should be defensive in a high... 
Via Benzinga
How Small Biotech Allogene Is Making Waves For Gilead, Novartis
Allogene Therapeutics said its donor cell-derived cancer treatment was successful for six months, and ALLO stock popped Thursday. 
Via Investor's Business Daily
This Top Healthcare Dividend Stock Is a Bargain Right Now
Gilead Sciences' revenues are being boosted by its COVID-19 treatment, but it will still be a good investment in a post-pandemic world. 
Via The Motley Fool
Exposures COVID-19
2 High-Yield Dividend Stocks to Buy Now
They pay more than double what you'd earn with the average stock in the S&P 500. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
This High-Quality, Cheap Stock Is Rated A “Buy” And Looks 10% Undervalued
Morningstar rates GILD as a 4-star stock, with a fair value estimate of $81.00. CFRA rates GILD as a 3-star “HOLD”, with a 12-month target price of $66.00. 
Via Talk Markets
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
Why Humanigen Stock Vaulted Higher Today
Detailed results from a late-stage study of the company's lead candidate were published online. 
Via The Motley Fool
Exposures COVID-19
Dogecoin Fulfills 'Doge Day' Goal Of 69 Cents Weeks Later, Surpasses Snapchat, GM In Valuation
The joke cryptocurrency Dogecoin (DOGE) touched a fresh all-time high in the early hours of Wednesday, crossing the much sought-af... 
Via Benzinga
Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir. 
Via The Motley Fool
2 Must-Own Biotech Stocks To Buy In May
After a stellar rally in 2020, biotech stocks have been selling off over the past couple of months. This offers investors a buying opportunity to scoop up quality biotech stocks such as Gilead Sciences... 
Via Talk Markets
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
Here's the list of some unusual options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest... 
Via Benzinga
Biopharma Stocks Stall After Earnings, Lag Over 52 Weeks
It is hard to forecast with the current choppy setting in the biopharma sector, but assuming that the COVID-19 vaccinations are on track in the U.S., financial results should improve for most large-cap... 
Via Talk Markets
Exposures COVID-19
Gilead Shares Slide After Light HIV Drug Sales Hit Q1 Earnings
Gilead Sciences Inc (NASDAQ: GILD) reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but... 
Via Benzinga
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
Gilead's Q1 Results Show Just How Much the Biotech Is Relying on Its COVID Drug
With Veklury, Gilead delivered solid revenue growth in Q1. Without the COVID drug, it was an entirely different story. 
Via The Motley Fool
Gilead Sciences (GILD) Q1 2021 Earnings Call Transcript
GILD earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.